These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3912730)

  • 1. [1st seminar of the Study Group on Bone Marrow Grafting on immunodepletion in the prevention of the graft-vs-host reaction. Marseilles, France, 4-6 October 1984. Abstracts].
    Nouv Rev Fr Hematol (1978); 1985; 27(6):351-75. PubMed ID: 3912730
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prevention of graft versus host disease by in vitro immunodepletion of the graft].
    Maraninchi D
    Nouv Rev Fr Hematol (1978); 1985; 27(6):349-50. PubMed ID: 3912729
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary disease following allografting.
    Jacobsohn DA
    Haematologica; 2005 Oct; 90(10):1301B. PubMed ID: 16219559
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of graft-versus-host disease by Fab fragments derived from ALG.
    Richie ER; Gallagher MT; Trentin JJ
    Transplant Proc; 1973 Mar; 5(1):873-6. PubMed ID: 4144467
    [No Abstract]   [Full Text] [Related]  

  • 5. Lymphocyte depletion in bone marrow transplantation: will modulation of graft-versus-host disease prove to be superior to prevention?
    Noga SJ; Hess AD
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):28-33. PubMed ID: 8211214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of graft-versus-host disease after bone marrow and small bowel transplantation by ultraviolet B modulation of bone marrow cells.
    Chowdhury NC; Jin MX; Hardy MA; Oluwole SF
    Transplant Proc; 1993 Feb; 25(1 Pt 1):475-6. PubMed ID: 8438384
    [No Abstract]   [Full Text] [Related]  

  • 7. Adaptive phenomena in bone marrow transplantation.
    Goujet-Zalc C; Ilbery PL
    Exp Hematol; 1973; 1(1):3-10. PubMed ID: 4154047
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of monoclonal antibodies in human bone marrow transplantation.
    Neudorf SM; Filipovich AH; Kersey JH
    Prog Clin Biol Res; 1984; 149():367-77. PubMed ID: 6377327
    [No Abstract]   [Full Text] [Related]  

  • 9. Bone marrow transplantation with ciclosporin.
    Gratwohl A; Speck B
    Prog Allergy; 1986; 38():404-31. PubMed ID: 3523495
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of donor bone marrow with OKT3 (PAN-T monoclonal antibody) for prophylaxis of graft-vs.-host disease (GvHD) in histocompatible allogeneic bone marrow transplantation (BMT): a pilot study.
    Filipovich AH; McGlave P; Ramsay NK; Goldstein G; Kersey JH
    J Clin Immunol; 1982 Jul; 2(3 Suppl):154S-157S. PubMed ID: 6752174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of vascularized bone marrow transplantation: current status and future clinical applications.
    Gordon CR; Tai CY; Suzuki H; Strande LF; Ramsamooj R; Matthews MS; Black KS; Hewitt CW
    Microsurgery; 2007; 27(4):348-53. PubMed ID: 17477415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of graft-versus-host disease in the isolated vascularized bone marrow transplant.
    Tai CY; Strande LF; Eydelman R; Sheng X; VanTran JL; Matthews MS; Hewitt CW
    Transplantation; 2004 Jan; 77(2):316-9. PubMed ID: 14743002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of posttransplant cyclosporine treatment on the development of syngeneic GVHD in recipients of UV-B irradiated bone marrow cells.
    Ohajekwe OA; Hardy MA; Oluwole SF
    Transplant Proc; 1995 Feb; 27(1):1385. PubMed ID: 7878922
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antilymphocytic antibodies and marrow transplantation. IV. Comparison of the effects of antibody fragments directed against immunoglobulin or lymphocyte antigens on acute secondary disease.
    Rodt H; Therfelder S; Eulitz M
    Exp Hematol; 1974; 2(4):195-203. PubMed ID: 4156327
    [No Abstract]   [Full Text] [Related]  

  • 16. Vascularized bone marrow transplantation and graft versus host disease: morphometric analysis of muscle.
    Woolley DS; Hou A; Strande L; Tatem L; Mathews M; Hewitt CW
    Transplant Proc; 1994 Dec; 26(6):3321-2. PubMed ID: 7998154
    [No Abstract]   [Full Text] [Related]  

  • 17. Multilineage amplification of graft-vs-host disease-resistant chimerism following rat vascularized bone marrow allotransplantation.
    Llull R; Murase N; Demetris AJ; Ye Q; Manez R; Starzl TE
    Transplant Proc; 1995 Aug; 27(4):2363-4. PubMed ID: 7544504
    [No Abstract]   [Full Text] [Related]  

  • 18. Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia.
    Champlin R
    Exp Hematol; 1995 Oct; 23(11):1148-51. PubMed ID: 7556522
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
    Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
    J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.